Exelixis: Hold Rating Maintained Amidst Comparable Efficacy and Risks of Zanza and Cabo
Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from ...
Promising Outlook for Exelixis’s Zanza: Strong Trial Results and Financial Prospects Support Buy Rating
Jefferies analyst Akash Tewari maintained a Buy rating on Exelixis (EXEL – Research Report) today and set a price target of $42.00.Invest with ...
Exelixis's SWOT analysis: cabo strength drives stock amid IP challenges
Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.32 billion focused on developing and commercializing new medicines for difficult-to-treat cancers, has been ...
Truist raises Exelixis stock target to $43 on Zanza optimism
Truist Securities increased its price target for Exelixis (NASDAQ:EXEL) shares to $43.00, up from the previous target of $42.00, while reaffirming a Buy rating on the stock. The new target represents ...
Investing7d
Exelixis's SWOT analysis: cabozantinib growth and zanzalintinib potential buoy stock
Beyond cabozantinib, Exelixis is advancing zanzalintinib (zanza) as its next potential blockbuster. Zanzalintinib is currently being evaluated in multiple pivotal trials, with data readouts ...
cweb14d
Exelixis’ Price Target Raised at Truist, Shares Rise 2 percent
Exelixis (NASDAQ:EXEL) shares rose more than 2% intra-day today after Truist Securities analysts increased their price target on the stock to $42, up from $38, while reaffirming a Buy rating. The move ...